Isoxanthanol has protective and anti-inflammatory effects on subchondral bone deterioration in experimental osteoarthritic rat model.

Abstract

In the present study isoxanthanol was investigated for treatment of monosodium iodoacetate (MIA)-induced osteoarthritis (OA) in vivo. The study demonstrated that isoxanthanol inhibited excessive release of interleukin-6, NO and PGE2 in RAW264.7 cells treated with LPS in dose dependent manner. The effects of isoxanthanol were examined in a rat model of osteoarthritis (OA) and observed to amelio-rate inflammatory damage and protect against OA. Moreover, in vivo data also confirmed inhibition of interleukin-6, NO and PGE2 levels in LPS-induced OA-rats. Deterioration of knee subchondral bone in LPS-induced OA-rats was also prevented effectively by isoxanthanol-treatment. Therefore, isoxanthanol prevents subchondral bone deterioration in OA rats via targeting inflammatory processes.

• Authors: Xin Li, Jie Yu, Yan Zhao, Yating Bai, Lixin Fu, Zilong Ma, Shuqin Zhang
• Journal: Acta biochimica Polonica (Acta Biochim Pol) Vol. 69 Issue 1 Pg. 65-69 (Feb 07 2022) ISSN: 1734-154X [Electronic] Poland
• PMID: 35129942 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Interleukin-6
• Plant Extracts
• Protective Agents
• Sesquiterpenes
• Nitric Oxide
• Dinoprostone

Topics

• Animals
• Anti-Inflammatory Agents (pharmacology)
• Arthritis, Experimental (drug therapy, metabolism)
• Bone and Bones (metabolism)
• Dinoprostone (metabolism)
• Disease Models, Animal
• Interleukin-6 (metabolism)
• Male
• Mice
• Nitric Oxide (metabolism)
• Osteoarthritis (drug therapy, metabolism)
• Plant Extracts (pharmacology)
• Protective Agents (pharmacology)
• RAW 264.7 Cells
• Rats
• Rats, Sprague-Dawley
• Sesquiterpenes (pharmacology)
• Xanthium (chemistry)